Literature DB >> 6927286

Antiviral activity of sodium 5-aminosulfonyl-2,4-dichlorobenzoate (M12325).

H Ohnishi, K Yamaguchi, S Shimada, S Himuro, Y Suzuki.   

Abstract

Sodium 5-aminosulfonyl-2,4-dichlorobenzoate (M12325) was evaluated for antiviral activity in tissue culture and infected mice. At concentrations ranging from 2.5 to 75.8 micrograms/ml, M12325 inhibited the cytopathic effects of 10 mean tissue culture infective doses of influenza virus A/WSN, A/FM, A/Kumamoto, and B/Great Lakes; parainfluenza virus; rhinovirus; echovirus; respiratory syncytial virus; and vesicular stomatitis virus. Concentrations up to 150 micrograms/ml did not inhibit the cytopathic effects of herpes simplex virus, vaccinia virus, or adenovirus. Concentrations up to 3,160 micrograms/ml did not inhibit the growth of MDCK, Vero, or HEL cells in culture. Single oral doses of M12325, ranging from 10 to 300 mg/kg, administered 1 h before and 1 h after challenge, reduced mortality in mice inoculated intranasally with influenza A/WSN virus. Twice daily oral doses for 14 days effected significant reductions in the mortality of mice infected intranasally with influenza A/WSN, A/FM, A/Kumamoto, and B/Great Lakes, and parainfluenza virus, but they were not effective in mice infected with herpes simplex virus. Multiple doses of 10 and 30 mg/kg, administered intraperitoneally, reduced lung consolidation and virus titer. M12325 was well tolerated in multiple doses up to 1 g/kg orally. These observations support the conclusions that M12325 has a broad spectrum of activity against RNA viruses in vitro and in vivo, selective toxicity, and a large margin of safety.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6927286      PMCID: PMC183720          DOI: 10.1128/AAC.22.2.250

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Variables influencing the in vitro susceptibilities of herpes simplex viruses to antiviral drugs.

Authors:  M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1974-07       Impact factor: 5.191

2.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

3.  THE IN VIVO ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). I. PROPHYLACTIC AND THERAPEUTIC ACTIVITY AGAINST INFLUENZA VIRUSES.

Authors:  R R GRUNERT; J W MCGAHEN; W L DAVIES
Journal:  Virology       Date:  1965-06       Impact factor: 3.616

4.  Amantadine-resistant and -sensitive influenza A strains and recombinants.

Authors:  C Scholtissek; G P Faulkner
Journal:  J Gen Virol       Date:  1979-09       Impact factor: 3.891

5.  3-Deazauridine: inhibition of ribonucleic acid virus-induced cytopathogenic effects in vitro.

Authors:  W M Shannon; G Arnett; F M Schabel
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

6.  A new antirhinovirus compound, ICI 73602: structure, properties, and spectrum of activity.

Authors:  D L Swallow; R A Bucknall; W E Stanier; A Hutchinson; H Gaskin
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

  6 in total
  6 in total

1.  Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt.

Authors:  J M Colacino; D C DeLong; J R Nelson; W A Spitzer; J Tang; F Victor; C Y Wu
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Antirhinovirus activity of purine nucleoside analogs.

Authors:  E De Clercq; R Bernaerts; D E Bergstrom; M J Robins; J A Montgomery; A Holy
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

3.  Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.

Authors:  Terrence M Tumpey; Adolfo García-Sastre; Andrea Mikulasova; Jeffery K Taubenberger; David E Swayne; Peter Palese; Christopher F Basler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-04       Impact factor: 11.205

4.  Chapter 12. Antiviral Agents.

Authors:  James L Kelley
Journal:  Annu Rep Med Chem       Date:  2008-04-10       Impact factor: 1.059

5.  Chapter 7 Orthomyxovirus infections.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29

6.  Chapter 3 Antiviral drugs: general considerations.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.